Ronald Knobloch, MD
Urology · Fort Smith, ARNPI 1962454710
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in AR, where the typical reported total is $5,249.
Across 265 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$625
- Astellas Pharma US Inc$507
- Coloplast$459
- Bayer$362
- Sumitomo Pharma America, Inc.$296
- Myriad Genetic Laboratories, Inc.$258
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,00395%
- Education$2465%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $625 |
| Astellas Pharma US Inc | 26 | $507 |
| Coloplast | 14 | $459 |
| Bayer | 17 | $362 |
| Sumitomo Pharma America, Inc. | 17 | $296 |
| Myriad Genetic Laboratories, Inc. | 13 | $258 |
| AbbVie(2 entities) | 14 | $247 |
| Boston Scientific | 14 | $229 |
| Procept Biorobotics Corporation | 4 | $227 |
| Antares Pharma, Inc. | 15 | $227 |
| Urogen Pharma, Inc. | 10 | $219 |
| Myovant Sciences Inc. | 13 | $213 |
| Pfizer | 11 | $205 |
| Olympus America Inc. | 14 | $205 |
| Medtronic(2 entities) | 9 | $191 |
| Axonics, Inc. | 6 | $96 |
| Merck | 6 | $91 |
| Blue Earth Diagnostics | 4 | $90 |
| Dendreon Pharmaceuticals LLC | 4 | $76 |
| Rochester Medical Corporation | 4 | $74 |
| Cook Medical LLC | 3 | $39 |
| Accord Healthcare, Inc. | 2 | $36 |
| Ambu Inc. | 1 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $32 |
| Urovant Sciences Inc | 2 | $29 |
| AstraZeneca | 2 | $27 |
| 180 Medical, Inc. | 1 | $27 |
| Innovation Technologies Inc | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Neotract Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$207
- AquaBeam Robotic System$169
How this compares
$5,249 in reported general payments places this provider in the 50th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 26 | $14,820 |
| Tamsulosin Hcl | 756 | $10,975 |
| Dutasteride | 130 | $3,152 |
| Solifenacin Succinate | 48 | $2,746 |
| Finasteride | 150 | $2,119 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 41 | $2,041 |
| Oxybutynin Chloride | 80 | $1,744 |
| Methenamine Hippurate | 23 | $1,222 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 15 | $1,129 |
| Testosterone Cypionate | 28 | $774 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $699 |
| Silodosin | 18 | $406 |
| Desmopressin Acetate | 15 | $362 |
| Ciprofloxacin Hcl | 23 | $304 |
| Doxazosin Mesylate | 35 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $296 | $14,82026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 88 urology providers in Arkansas.
Other urology in Fort Smith
- Kyle BashamFort Smith$30K
- John TerrellFort Smith$12K
- John LangeFort Smith$2K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.